{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:38:16Z","timestamp":1785587896866,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Once-daily and once-weekly injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are established in obesity and type 2 diabetes mellitus (T2DM). In T2DM, both once-daily and once-weekly insulin are expected to be available. This study elicited utilities associated with these treatment regimens from members of the general public in the UK, Canada, and China, to quantify administration-related disutility of more-frequent injectable treatment, and allow economic modelling.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two anchor states (no pharmacological treatment), and seven treatment states (daily oral tablet and generic injectable regimens of variable frequency), with identical outcomes were tested A broadly representative sample of the general public in each country participated (excluding individuals with diabetes or pharmacologically treated obesity). An adapted <jats:italic>Measurement and Valuation of Health<\/jats:italic> protocol was administered 1:1 in web-enabled interviews by trained moderators: visual analogue scale (VAS) as a \u201cwarm-up\u201d, and time trade-off (TTO) using a 20-year time horizon for utility elicitation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 310 individuals participated. The average disutility of once-daily versus once-weekly GLP-1 RA was \u2212\u20090.048 in obesity and \u2212\u20090.033 in T2DM; the corresponding average disutility for insulin was \u2212\u20090.064. Disutilities were substantially greater in China, relative to UK and Canada.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Within obesity and T2DM, more-frequent treatment health states had lower utility. Scores by VAS also followed a logical order. The generated utility values are suitable for use in modelling injectable therapy regimens in obesity and T2DM, due to the use of generic descriptions and assumption of equal efficacy. Future research could examine the reasons for greater administration-related disutility in China.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01470-w","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T15:02:37Z","timestamp":1652022157000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China"],"prefix":"10.1007","volume":"24","author":[{"given":"Phil","family":"McEwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Baker-Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rg","family":"\u00c1sbj\u00f6rnsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunni","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M.A., et al.: GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art. Mol. Metab. 46, 101102 (2021)","journal-title":"Mol. Metab."},{"key":"1470_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","author":"JP Wilding","year":"2021","unstructured":"Wilding, J.P., et al.: Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. (2021). https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N. Engl. J. Med."},{"issue":"1133","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","volume":"96","author":"KH Sheahan","year":"2020","unstructured":"Sheahan, K.H., Wahlberg, E.A., Gilbert, M.P.: An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med. J. 96(1133), 156\u2013161 (2020)","journal-title":"Postgrad. Med. J."},{"key":"1470_CR4","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo, J.M., Nuffer, W., Smith, B.A.: GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 12, 2042018821997320 (2021)","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"2","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"Buse, J.B., et al.: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2), 221\u2013228 (2020)","journal-title":"Diabetologia"},{"issue":"7","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.clinthera.2016.05.009","volume":"38","author":"CV Spain","year":"2016","unstructured":"Spain, C.V., et al.: Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin. Ther. 38(7), 1653-1664. e1 (2016)","journal-title":"Clin. Ther."},{"issue":"2","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","volume":"4","author":"L-E Garcia-Perez","year":"2013","unstructured":"Garcia-Perez, L.-E., et al.: Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 4(2), 175\u2013194 (2013)","journal-title":"Diabetes Ther."},{"issue":"2","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","volume":"13","author":"WH Polonsky","year":"2011","unstructured":"Polonsky, W.H., et al.: Patient perspectives on once-weekly medications for diabetes. Diabetes Obes. Metab. 13(2), 144\u2013149 (2011)","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","volume":"26","author":"JH Best","year":"2009","unstructured":"Best, J.H., et al.: Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet. Med. 26(7), 722\u2013728 (2009)","journal-title":"Diabet. Med."},{"key":"1470_CR10","unstructured":"Tolley, K.: What are health utilities. Hayward Medical Communications (2009)"},{"key":"1470_CR11","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 - Chapter 5: The reference case. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case (2013)"},{"key":"1470_CR12","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada, 4th edn. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf (2017)"},{"key":"1470_CR13","unstructured":"International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic Guidelines Around The World - China Mainland. https:\/\/tools.ispor.org\/PEguidelines\/countrydet.asp?c=28&t=4 (2018)"},{"key":"1470_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.12.017","author":"LS Matza","year":"2021","unstructured":"Matza, L.S., et al.: Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health (2021). https:\/\/doi.org\/10.1016\/j.jval.2020.12.017","journal-title":"Value Health"},{"key":"1470_CR15","unstructured":"Brazier, J., Rowen, D.: NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet] (2011)"},{"issue":"8","key":"1470_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/13696998.2019.1609482","volume":"22","author":"KS Boye","year":"2019","unstructured":"Boye, K.S., et al.: Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J. Med. Econ. 22(8), 806\u2013813 (2019)","journal-title":"J. Med. Econ."},{"issue":"3","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye, K.S., et al.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12(3), 219\u2013230 (2011)","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2648-7","volume":"17","author":"LS Matza","year":"2017","unstructured":"Matza, L.S., et al.: Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv. Res. 17(1), 1\u201310 (2017)","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"1470_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.4158\/EP161199.RA","volume":"22","author":"X Shen","year":"2016","unstructured":"Shen, X., et al.: The diabetes epidemic in China: an integrated review of national surveys. Endocr. Pract. 22(9), 1119\u20131129 (2016)","journal-title":"Endocr. Pract."},{"key":"1470_CR20","unstructured":"Diabetes Canada. Clinical Practice Guidelines. https:\/\/www.diabetes.ca\/health-care-providers\/clinical-practice-guidelines\/chapter-1#panel-tab_FullText (2018)"},{"key":"1470_CR21","unstructured":"Diabetes UK. Number of people with diabetes reaches 4.7 million. https:\/\/www.diabetes.org.uk\/about_us\/news\/new-stats-people-living-with-diabetes (2019)"},{"issue":"1","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead, S.J., Ali, S.: Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull. 96(1), 5\u201321 (2010)","journal-title":"Br. Med. Bull."},{"issue":"10","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe, M., et al.: EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics 34(10), 993\u20131004 (2016)","journal-title":"Pharmacoeconomics"},{"key":"1470_CR24","unstructured":"EuroQol. EQ-5D-3L | Valuation. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/valuation\/ (2021)"},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095\u20131108 (1997)","journal-title":"Med. Care"},{"issue":"6","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza, L.S., et al.: Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health 24(6), 812\u2013821 (2021)","journal-title":"Value Health"},{"issue":"7","key":"1470_CR27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","volume":"30","author":"LS Matza","year":"2021","unstructured":"Matza, L.S., et al.: Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual. Life Res. 30(7), 2033\u20132043 (2021)","journal-title":"Qual. Life Res."},{"issue":"3","key":"1470_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1524-4733.2007.00260.x","volume":"11","author":"SL Dennett","year":"2008","unstructured":"Dennett, S.L., Boye, K.S., Yurgin, N.R.: The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 11(3), 478\u2013486 (2008)","journal-title":"Value Health"},{"issue":"12","key":"1470_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209344","volume":"13","author":"H-W Lin","year":"2018","unstructured":"Lin, H.-W., et al.: Valuation of the EQ-5D-5L in Taiwan. PLoS ONE 13(12), e0209344 (2018)","journal-title":"PLoS ONE"},{"issue":"8","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10198-014-0635-z","volume":"16","author":"P Wang","year":"2015","unstructured":"Wang, P., et al.: Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese. Eur. J. Health Econ. 16(8), 857\u2013863 (2015)","journal-title":"Eur. J. Health Econ."},{"issue":"4","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11136-015-1129-x","volume":"25","author":"X Jin","year":"2016","unstructured":"Jin, X., et al.: Is bad living better than good death? Impact of demographic and cultural factors on health state preference. Qual. Life Res. 25(4), 979\u2013986 (2016)","journal-title":"Qual. Life Res."},{"issue":"1","key":"1470_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13300-019-00718-8","volume":"11","author":"LS Matza","year":"2020","unstructured":"Matza, L.S., et al.: Patient preferences and health state utilities associated with mealtime insulin concentrations among patients with diabetes in Italy. Diabetes Ther. 11(1), 319\u2013330 (2020)","journal-title":"Diabetes Ther."},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.vhri.2015.11.006","volume":"9","author":"N Rajan","year":"2016","unstructured":"Rajan, N., et al.: Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg. Issues 9, 67\u201371 (2016)","journal-title":"Value Health Reg. Issues"},{"issue":"7","key":"1470_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","volume":"16","author":"LS Matza","year":"2007","unstructured":"Matza, L.S., et al.: Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual. Life Res. 16(7), 1251\u20131265 (2007)","journal-title":"Qual. Life Res."},{"issue":"7","key":"1470_CR35","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s13300-021-01054-6","volume":"12","author":"H Gelhorn","year":"2021","unstructured":"Gelhorn, H., et al.: The burden of type 2 diabetes and the value of achieving near normoglycemia from the patient perspective. Diabetes Ther. 12(7), 1821\u20131837 (2021)","journal-title":"Diabetes Ther."},{"issue":"9","key":"1470_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/dom.12091","volume":"15","author":"HL Gelhorn","year":"2013","unstructured":"Gelhorn, H.L., et al.: Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes. Metab. 15(9), 802\u2013809 (2013)","journal-title":"Diabetes Obes. Metab."},{"key":"1470_CR37","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"J Brazier","year":"2017","unstructured":"Brazier, J., et al.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, Oxford (2017)"},{"key":"1470_CR38","unstructured":"Office for National Statistics. 2011 Census. https:\/\/www.ons.gov.uk\/census\/2011census (2011)"},{"key":"1470_CR39","unstructured":"Office for National Statistics. Employment in the UK: December 2019. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/employmentandemployeetypes\/bulletins\/employmentintheuk\/december2019 (2019)"},{"key":"1470_CR40","unstructured":"Office for National Statistics. Highest level of qualification achieved by people living in UK regions, 2010 to 2018. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/educationandchildcare\/adhocs\/10516highestlevelofqualificationachievedbypeoplelivinginukregions2010to2018 (2019)"},{"key":"1470_CR41","unstructured":"Office for National Statistics. Population estimates by marital status and living arrangements, England and Wales. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesbymaritalstatusandlivingarrangements (2019)"},{"key":"1470_CR42","unstructured":"Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2018. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/latest (2019)"},{"key":"1470_CR43","unstructured":"Statistics Canada. Highest level of educational attainment (detailed) by selected age groups 25 to 64, both sexes, % distribution 2016, Canada, provinces and territories, 2016 Census \u2013 25% Sample data. https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/hlt-fst\/edu-sco\/Table.cfm?Lang=E&T=21&Geo=00&View=2&Age=2 (2017)"},{"key":"1470_CR44","unstructured":"Organisation for Economic Co-operation and Development. Education at a Glance 2019 - People's Republic of China. https:\/\/www.oecd.org\/education\/education-at-a-glance\/EAG2019_CN_CHN.pdf (2019)"},{"key":"1470_CR45","unstructured":"Statista. Population distribution in China in 2020, by broad age group. https:\/\/www.statista.com\/statistics\/251524\/population-distribution-by-age-group-in-china\/ (2021)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01470-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01470-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01470-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T09:05:13Z","timestamp":1677920713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01470-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01470-w","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,8]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adelphi Values PROVE were contracted by Novo Nordisk to conduct and report this research. James Baker-Knight is an employee of Novo Nordisk. Bj\u00f6rg \u00c1sbj\u00f6rnsd\u00f3ttir is an employee of Novo Nordisk. Phil McEwan is a paid consultant of Novo Nordisk. Yunni Yi, Aimee Fox, and Robin Wyn are employees of Adelphi Values PROVE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}